
Adaptimmune TherapeuticsPharmaceutical Companies
ATIVESITE | Adaptimmune reports updated SURPASS data at ESMO 2021
Adrian Rawcliffe, CEO, and Elliot Norry, CMO – present Adaptimmune’s SURPASS trial data and the Company’s perspective on these results. Clinical responses across 5 solid tumor indications.
Source Adaptimmune Therapeutics
YouTube